Evidence map›Paper›PMID 41832487›Full record

ArticleJournal of nanobiotechnology2026

CD93-targeted resveratrol-loaded PLGA nanoparticles remodel CD8⁺ T cell metabolism through AIF-mediated oxidative phosphorylation to overcome lung cancer immunotherapy resistance.

Zhou Jiang, Yuning Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zhou JiangDepartment of Thoracic Medicine, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, No. 283 Tongzipo Road, Yuelu District, Changsha, 410006, Hunan Province, China. jiangzhou@hnca.org.cn.
Yuning LiDepartment of Thoracic Medicine, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, No. 283 Tongzipo Road, Yuelu District, Changsha, 410006, Hunan Province, China.

Funding

the Hunan Provincial Natural Science Foundation No. 2023JJ40406
6 · The paper itself

Abstract

Lung cancer (LC) remains a leading cause of cancer-related mortality worldwide, and the limited efficacy of immunotherapy due to treatment resistance underscores the urgent need for new therapeutic strategies. In the present study, CD93-targeted poly(lactic-co-glycolic acid) (PLGA) nanoparticles encapsulating resveratrol (CD93-NPs@RSV) were developed to remodel the metabolic fitness of CD8

Indexed as

CD8-Positive T-LymphocytesLung NeoplasmsMembrane GlycoproteinsNanoparticlesPolylactic Acid-Polyglycolic Acid CopolymerResveratrolAnimalsCell Line, TumorHumansImmunotherapyMiceMice, Inbred C57BLOxidative PhosphorylationTumor MicroenvironmentMembrane GlycoproteinsPolylactic Acid-Polyglycolic Acid CopolymerResveratrolCD93-targeted nanoparticlesLung cancer immunotherapy resistanceMitochondrial metabolic reprogrammingOxidative phosphorylationResveratrol

Identifiers

PMID41832487
PMCPMC13104583

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.